ClinicalTrials.gg
Active, not recruitingNCT07533175AMAZE 2Updated Nov 6, 2026

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

A Phase 3 interventional study of NNC0487-0111 and Placebo (matched to NNC0487-0111) in Diabetes Mellitus, Overweight and Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 73 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Updated Nov 6, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
638
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.

Planned enrollment
48th of 494
638 · median 87
Started
2026
with 1 other
Phase 3
182 of 642
none open now
Registered
641st of 642
by date

Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 48th largest by planned enrollment of the 494 interventional ones that give a count, is one of 2 that started in 2026, is one of 182 in phase 3, and was the 641st registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 642 studies in Diabetes Mellitus by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.

03

Conditions studied

  • Diabetes Mellitus
  • Overweight
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex at birth).
  • Age 18 years or above at the time of signing .
  • Diagnosed with type 2 diabetes mellitus more than equal to (≥) 180 days before screening.
  • Treatment with lifestyle intervention, and/or 0-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i), thiazolidinediones, or sulfonylureas (SU) as a single agent or in combination) according to local label. Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) before screening.
  • (HbA1c) 7-10% [53-86 (millimoles per mole) mmol/mol] (both inclusive) as measured by the central laboratory at screening.

Exclusion criteria

Exclusion Criteria:

  • Renal impairment with estimated (eGFR) less than (\<) 30 milliliter per minute per meter square (mL/min/1.73 m\^2) [2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula], at screening.
  • Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) before screening or are expected to require treatment after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8.
  • Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator.
  • Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
638 participants (estimated)

Study arms

  • Experimental
    NNC0487-0111 dose level 1

    Participants will be randomized to receive NNC0487-0111 dose level 1 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: NNC0487-0111

  • Experimental
    NNC0487-0111 dose level 2

    Participants will be randomized to receive NNC0487-0111 dose level 2 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: NNC0487-0111

  • Experimental
    NNC0487-0111 dose level 3

    Participants will be randomized to receive NNC0487-0111 dose level 3 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: NNC0487-0111

  • Experimental
    NNC0487-0111 dose level 4

    Participants will be randomized to receive NNC0487-0111 dose level 4 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: NNC0487-0111

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Placebo (matched to NNC0487-0111)

Interventions

  • NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • DrugPlacebo (matched to NNC0487-0111)

    Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

06

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured as percentage (%) of body weight.

    Time frame: From baseline (week 0) to (week 84)

Secondary outcomes

  1. Change in waist circumference

    Measured as centimetre (cm).

    Time frame: From baseline (week 0) to (week 84)

  2. Change in glycated haemoglobin (HbA1c)

    Measured as percentage (%) of HbA1c.

    Time frame: From baseline (week 0) to (week 84)

  3. Change in systolic blood pressure (SBP)

    Measured as millimetre of mercury (mmHg).

    Time frame: From baseline (week 0) to (week 84)

  4. Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) physical function score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. The physical function score ranges from 0-100. Higher scores indicate better levels of functioning.

    Time frame: From baseline (week 0) to (week 84)

  5. Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score

    Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation (SD) of 10. The physical functioning ranges from 19.0 to 57.6. Higher scores indicate better functional health and well-being.

    Time frame: From baseline (week 0) to (week 84)

  6. Change in body weight

    Measured as kilogram (kg).

    Time frame: From baseline (week 0) to (week 84)

  7. Change in body mass index (BMI)

    Measured as kilograms per meter squared (kg/m\^2).

    Time frame: From baseline (week 0) to (week 84)

  8. Change in IWQOL-Lite-CT: Physical, Psychosocial, Total score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. The physical function score ranges from 0-100. Higher scores indicate better levels of functioning.

    Time frame: From baseline (week 0) to (week 84)

  9. Achievement of HbA1c < 7.0% (Yes/No)

    Measured as number of participants

    Time frame: From baseline (week 0) to (week 84)

  10. Achievement of HbA1c ≤ 6.5% (Yes/No)

    Measured as number of participants

    Time frame: From baseline (week 0) to (week 84)

  11. Achievement of HbA1c < 5.7% (Yes/No)

    Measured as number of participants

    Time frame: From baseline (week 0) to (week 84)

  12. Change in fasting plasma glucose (FPG) (mmol/L)

    Measured as millimoles per liter (mmol/L)

    Time frame: From baseline (week 0) to (week 84)

  13. Change in fasting plasma glucose (FPG) (mg/dL)

    Measured as milligram per deciliter (mg/dL)

    Time frame: From baseline (week 0) to (week 84)

  14. Change in fasting insulin

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 84)

  15. Change in urinary albumin-to-creatinine ratio (UACR)

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 84)

  16. Change in diastolic blood pressure

    Measured as mmHg.

    Time frame: From baseline (week 0) to (week 84)

  17. Change in high-sensitivity C-reactive protein (hsCRP)

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 84)

  18. Number of Treatment Emergent Adverse Events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to week 88

  19. Number of Treatment Emergent Serious Adverse Events (TESAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to week 88

  20. Number of Treatment Emergent Adverse Events (TEAEs) leading to permanent treatment discontinuation

    Measured as count of events.

    Time frame: From baseline (week 0) to week 88

  21. Number of treatment emergent clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL), confirmed by a blood glucose (BG) meter)

    Measured as number of episodes

    Time frame: From baseline (week 0) to week 88

  22. Number of treatment emergent severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as number of episodes

    Time frame: From baseline (week 0) to week 88

  23. Change in Total cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 84)

  24. Change in High-density lipoprotein (HDL) cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 84)

  25. Change in Low-density lipoprotein (LDL) cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 84)

  26. Change in Very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 84)

  27. Change in Non-HDL cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 84)

  28. Change in Triglycerides

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 84)

07

Study locations

73 sites
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2028, 27 months after the start.

Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's planned 27 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 16, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Aug 7, 2028
CompletionEst.
Aug 7, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 6, 2026
Sites
1 site removed. A.O.U Policlinico Paolo Giaccone - U.O.C Medicina Interna is now Recruiting
Show 1 removed
  • ARETEUS s.r.o. · Trebišov, Slovakia
across 2 updates, Sep 30, 2026 – Nov 6, 2026
Enrollment
630→638
Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Recruiting→Active, not recruiting
    1 site removed
    Show 1 removed
    • ARETEUS s.r.o. · Trebišov, Slovakia
    Enrollment 630→638
    + 2 other changes: verification date and contact details
  2. Sep 30, 2026
    A.O.U Policlinico Paolo Giaccone - U.O.C Medicina Interna is now Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07533175
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Apr 13, 2026
Primary completion
Aug 7, 2028 (estimated)
Completion
Aug 7, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion